Prostate Cancer

Choosing treatment for stage 2 prostate cancer? Get the facts on surgery versus radiation and learn to manage possible side effects such as erectile dysfunction.

In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in high-risk localized prostate cancer.

Adding Truqap to Zytiga, prednisone, and ADT extended radiographic progression-free survival by 7.5 months in PTEN-deficient prostate cancer.

For patients with HRRm prostate cancer receiving Akeega with prednisone, quality of life remained at baseline.

Although death rates continue to decline each year, prostate cancer cases are increasing, especially those diagnosed at advanced stages.

This stage 1 prostate cancer guide explains diagnosis, Gleason scores and the choice between surgery, radiation and active surveillance.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

The FDA approved the denosumab biosimilars Enoby and Xtrenbo for patients on hormone therapies for breast or prostate cancer that weaken bones.

Patients with prostate cancer can position themselves to receive the best care possible by being seen by a multidisciplinary team of healthcare providers.

The NY Giants Legend To Celebrate Being Cancer Free At The NFL Giants Crucial Catch Game September 28th at MetLife Stadium.

Dr. David A. Taub sat down with CURE for an interview in honor of Prostate Cancer Awareness Month, observed annually each September.

This Prostate Cancer Awareness Month, a first-in-the-nation trial offers hope by using a targeted therapy before surgery to stop recurrence in its tracks.

The FDA approved Bosaya and Aukelso, biosimilars of Prolia and Xgeva, respectively, for the treatment of solid tumors, like breast and prostate cancer.

This comprehensive guide provides essential information to help patients and their families navigate their prostate cancer journey.

Dr. Paul Gellhaus says PSA testing and modern biopsy methods ease fears and reassure patients, making early prostate cancer detection safe and valuable.

The FDA has approved the NDA for Camcevi ETM for the treatment of advanced prostate cancer.

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about managing the emotional and mental health impact of prostate cancer for patients and caregivers.

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about managing side effects following prostate cancer treatment.

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about navigating treatment option in prostate cancer.

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA.

Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume should also guide treatment.

Being diagnosed with a disease like prostate cancer is a very impactful life event, making it vital to have people you love by your side.

A new AI precision medicine test is being used to help clinicians better identify a personalized treatment plan to treat patients with prostate cancer.

The FDA has granted fast track designation to HLD-0915 for metastatic castration-resistant prostate cancer.